The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients
Clinical trial NCT04902690 · UNKNOWN
Trial details
- NCT number
- NCT04902690
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-05-31
- Primary completion
- 2024-07-31
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.